Research on clinical features, magnetic resonance, characteristics of some biomarkers and initial treatment results of high grade of glial cell tumors

Tran Anh Duc1, Nguyen Van Ba1, Nguyen Duc Lien2
1 Military Hospital 103
2 K Hospital

Main Article Content

Abstract

Objectives: To investigate the clinical characteristics, magnetic resonance, P53 gene mutation, IDH of grade III and IV of glial cell tumors with the indication for surgery combined with radiotherapy and chemotherapy. Initial assessment of treatment results for high-level diabetic cancer. Subjects and research methods: Patients with high grade of glial cell tumors undergo surgery, histopathology diagnosis, immunohistochemistry to identify mutations (IDH, p53, MGMT) and radiotherapy and chemotherapy incorporated at K hospital. Tumor and combined chemotherapy. Evaluation of clinical symptoms at admission, tumor characteristics on magnetic resonance film, initial results after tumor removal surgery and based on the Karnofski scale to assess the patient's previous nervous system rehabilitation and after surgery. Results: Average age 45 ± 15.7, ratio male/female = 32/19. The main reasons for hospital admission of the patient were headache, hemiplegia, and epilepsy. Magnetic resonance imaging showed that most tumors have clear boundaries, mixed structure, heterogeneous signals, strong drug infiltration after injection, with cerebral edema around tumors but little surrounding invasion, no calcification or bleeding. The results of surgical treatment showed that over 90% of the patients were all taken and the majority of tumors were removed, the postoperative Karnofsky score increased more than before surgery, but the difference was not statistically significant. Conclusion: Patients with high grade of glial cell tumors have the main clinical symptoms of intracranial hypertension syndrome, characterized by well-defined, mixed-structure tumors. less invasive around. Surgical treatment for the majority of tumors showed an improvement in postoperative nervous system function.

Article Details

References

1. Ostrom QT, Liao P, Stetson LC et al., Epidermiology of glioblastoma and trends in Glioblastoma Survivorship. In: (eds) Brem S, Abdullah K.G, Glioblastoma, Elsevier, 2017; chapter 2: 11- 19
2. Sarkar A, Chiocca EA, Glioblastoma and malignan astocytoma. In: (eds) Kaye AH, Laws ER, Brains Tumors- An Encyclopedic Approach, Saunders Elseviers, 2012; 21: 384 – 407.
3. DeVita Jr VT, Hellman S, Steven A, Principles and practice of oncology, 7 ed. JB Lippincott, Philadelphia, 2005.
4. Hoffman S, Propp JM, McCarthy BJ, Temporal trends in incidence of primary brain tumors in the United States 1985-1999, Neuro Oncol, 2006; 8: 27-37.
5. Fisher JL, Schwartzbaum JA, Wrensch M, et al., Epidemiology of brain tumors. Neurol Clin, 2007; 25: 867-890.
6. Stupp R, Mason WP, van den Bent MJ, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 205; 352: 987-996.
7. Jennifer H, John O, Holly N, et al., Chemoirradiation for Glioblastoma Multiforme: The National Cancer Institute Experience, Plos One, 2013; 8 (8): 11-18.
8. Anh LT, Hoang NNB, Results of radiotherapy for astrocytoma after surgery by accelerator at Cho Ray Oncology Center. Presented at Conference on scientific and technical activities Cho Ray Hospital in HCM city, Vietnam, 2012.
9. Senft C, Bink A, Franz K, et al., Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial, Lancet Oncol, 2011; 12 (11): 997-1003.